Miragen, UT Southwestern Show miR-208 Inhibition Improves Survival in Rodent Heart-Failure Models | GenomeWeb

By Doug Macron

Researchers from Miragen Therapeutics and the University of Texas Southwestern Medial Center this week published data showing that an inhibitor of microRNA-208 could improve cardiac function and survival rates in mice during heart failure.

“Not only do these findings provide additional validation of miR-208 as a promising target for therapeutic intervention, but they also enhance our understanding of microRNA biology,” Miragen President and CEO Bill Marshall said in a statement.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.